삼출 나이관련황반변성에 대한 항혈관내피성장인자 유리체내주사 치료의 장기 임상 결과
Intravitreal Anti-vascular Endothelial Growth Factor Injections to Treat Neovascular Age-related Macular Degeneration: Long-term Treatment Outcomes
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
목적: 삼출 나이관련황반변성에 대한 유리체내 항혈관내피성장인자 주사 치료의 장기 결과를 알아보고자 한다. 대상과 방법: 삼출 나이관련황반변성 진단 후 treat-and-extend 또는 as needed 방법으로 7년 이상 유리체내 항혈관내피성장인자주사 치료를 시행 받은 환자들에 대한 후향적 의무기록 분석을 시행하였다. 주사 횟수, 최대교정시력 및 중심망막두께 등을 평가하였으며, 장기간 주사 치료에 따른 부작용 여부를 같이 조사하였다. 결과: 총 196명의 196안을 분석하였다(평균 나이 68.6 ± 9.6세, 여성 77명). 평균 78.0 ± 16.5개월 경과관찰하였고, 해당 기간 동안 평균 17.3 ± 13.5회의 유리체내주사가 시행되었다. 치료 전 측정한 최대교정시력은 평균 0.75 ± 0.58 logMAR, 중심망막두께는 349.7 ± 152.6 μm였고, 6개월째 두 수치 모두 최대 호전을 보였으나(p<0.05), 이후 점차 악화 소견을 보이며 7년째 최대교정시력 0.91 ± 0.78 logMAR, 중심망막두께 284.5 ± 105.8 μm로 확인되었다. 주사 후 7년째 시력은 치료 전 시력과 강한 양의 상관관계를 보였다. 장기간 주사 동안 총 11회의 안압상승 및 3회의 전방 내 염증 증가 소견이 있었으나 안내염 등의 심각한 부작용은 관찰되지 않았다. 결론: 삼출 나이관련황반변성에서 유리체내 항혈관내피성장인자 주사 치료 후 초기 6개월간의 최대 시력 호전이 있었으나 5년 이상 경과 시 지속적인 시력 저하를 막지 못하였다. 진단 당시 시력이 장기 시력예후와 관련된 중요 예측 인자로 판단되며 적극적인 유리체내주사 치료를 통해 더 나은 장기 시력 결과를 기대해 볼 수 있다.
Abstract
Purpose: We assessed the visual and anatomical outcomes, and the safety profile of long-term intravitreal anti-vascular endothelial growth factor (VEGF) injections (aflibercept, ranibizumab, and bevacizumab) given to treat neovascular age-related macular degeneration (NAMD). Methods: We analyzed medical records collected over 7 years of treatment-naive NAMD patients who received outpatient clinic- based intravitreal anti-VEGF injections. All were treated employing either “treat-and-extend” or “as needed” protocols at the discretion of the retinal specialist. The number of injections, adverse events associated with injection, and measures of visual acuity (VA), central foveal thickness (CFT), and intraocular pressure (IOP) were recorded. Results: Overall, we assessed 196 eyes of 196 patients (average age 68.6 ± 9.6 years; 77 females). Patients received an average of 17.3 ± 13.5 injections over 78.0 ± 16.5 months of clinical follow-up. The initial mean VA (logMAR) was 0.75 ± 0.58 and the CFT was 349.7 ± 152.6 μm. Both parameters exhibited maximal improvements at the 6-month visit (p < 0.05). However, the clinical outcomes worsened over the 7-year clinical course; the best-corrected visual acuity (BCVA) was 0.91 ± 0.78 and the CFT was 284.5 ± 105.8 μm at 7 years. The BCVA at 7 years was significantly correlated with the initial BCVA. IOP-related events increased 11-fold and anterior chamber reactions increased 3-fold over the years, but no significant complications such as endophthalmitis were recorded. Conclusions: The use of intravitreal anti-VEGF agents was associated with initial visual improvements over 6 months but did not prevent the worsening of NAMD over 5 years. The BCVA at the initial visit was a strong predictor of the final BCVA. A more intensive injection schedule might improve long-term outcomes.
참고문헌 (25)
- Wong TY, "The natural history and prognosis of neovascular age-related macular degeneration : a systematic review of the literature and meta-analysis", Ophthalmology, 115, pp.116~126 (2008)
- Park SJ, "Prevalence and incidence of exudative age-related macular degeneration in South Korea: a nationwide population-based study", Ophthalmology, 122, pp.2063~2070 (2015)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Heier JS, "Intravitreal aflibercept(VEGF trap-eye)in wet age-related macular degeneration", Ophthalmology, 119, pp.2537~2548 (2012)
- Grunwald JE, "Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials", Ophthalmology, 121, pp.150~161 (2014)
- Krüger Falk M, "Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment", Am J Ophthalmol, 155, pp.89~95 (2013)
- Zhu M, "Intravitreal ranibizumab for neovascular age-related macular degeneration in clinical practice : five-year treatment outcomes", Graefes Arch Clin Exp Ophthalmol, 253, pp.1217~1225 (2015)
- Berg K, "An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration", Acta Ophthalmol, 95, pp.796~802 (2017)
- Garweg JG, "The fate of eyes with wet AMD beyond four years of anti-VEGF therapy", Graefes Arch Clin Exp Ophthalmol, 256, pp.823~831 (2018)
- 장효주, "나이관련황반변성에 동반된 맥락막신생혈관에서 유리체내 라니비주맙 주사의 2년 장기 효과", 대한안과학회지, 54(9), pp.1359~1364 (2013), 대한안과학회
- DiLoreto DA Jr, "Use of best and final visual acuity outcomes in ophthalmological research", Arch Ophthalmol, 121, pp.1586~1590 (2003)
- Chong V, "Ranibizumab for the treatment of wet AMD : a summary of real-world studies", Eye(Lond), 30, pp.270~286 (2016)
- Frennesson CI, "A three-year follow-up of ranibizumab treatment of exudative AMD : impact on the outcome of carrying forward the last acuity observation in drop-outs", Acta Ophthalmol, 92, pp.216~220 (2014)
- Rofagha S, "Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON:a multicenter cohort study (SEVEN-UP)", Ophthalmology, 120, pp.2292~2299 (2013)
- Gillies MC, "Long-term outcomes of treatment of neovascular age-related macular degeneration : data from an observational study", Ophthalmology, 122, pp.1837~1845 (2015)
- Comparison of Age-related Macular Degeneration Treatments Trials(CATT)Research Group, "Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration : the comparison of age-related macular degeneration treatments trials", Ophthalmology, 123, pp.1751~1761 (2016)
- Peden MC, "Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration", Ophthalmology, 122, pp.803~808 (2015)
- Holz FG, "Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration", Br J Ophthalmol, 99, pp.220~226 (2015)
- Rasmussen A, "A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration", Ophthalmology, 120, pp.2630~2636 (2013)
- Grunwald JE, "Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials", Ophthalmology, 122, pp.809~816 (2015)
- Xu L, "Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration", Retina, 35, pp.176~186 (2015)
- Sarks J, "Development of atrophy of the retinal pigment epithelium around disciform scars", Br J Ophthalmol, 90, pp.442~446 (2006)
- Tanaka E, "Visionthreatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration", Ophthalmology, 122, pp.153~161 (2015)
- Munk MR, "Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration", Acta Ophthalmol, 94, pp.e757~e764 (2016)
- Bhisitkul RB, "Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study", Am J Ophthalmol, 159, pp.915~924 (2015)